Back to search

Article

Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d.<i>vs</i>40 mg b.i.d. The X-COVID19 Randomized Clinical Trial

2021-11-21

Abstract excerpt

<h4>Summary</h4> It is uncertain whether higher doses of anticoagulants than recommended for thromboprophylaxis are necessary in COVID-19 patients hospitalized in general wards. This is a multicentre, open-label, randomized trial performed in 9 Italian centres, comparing 40 mg b.i.d. vs 40 mg o.d. enoxaparin in COVID-19 patients, between April 30, 2020 and April 25, 2021. Primary efficacy outcome was in-hospital i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f678a9f1-5d59-51b6-bef4-9ea00e058a4f
DOI
10.1101/2021.11.17.21266488
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d.<i>vs</i>40 mg b.i.d. The X-COVID19 Randomized Clinical TrialDOI 10.1101/2021.11.17.21266488
Select a neighboring publication to make it the new centre.